NPR reports on a clinical trial examining an antisense oligonucleotide drug for Huntington's disease.
The test will run on Oxford Nanopore's MinIon and will be used as a reflex test when the standard PCR test does not give a clear answer.
The researchers studied edits generated by more than 40,000 gRNAs and gathered data for more than 109 mutational outcomes to create the software.
A UK woman sues a hospital for not telling her of her father's genetic testing results, the Guardian reports.
In Science this week: molecular drivers of small cell neuroendocrine carcinomas, and more.
In PLOS this week: Huntington's disease modifiers, possible new Chikungunya virus subgroup, and more.
Six microRNAs appeared to be present at enhanced levels in cerebrospinal fluid from symptom-free individuals with characteristic Huntington disease gene expansions.
According to Slate, some people prefer not to know their genetic risk of certain diseases.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.
The researchers observed that eliminating these microsatellite repeat expansion RNAs in patient cells reversed some hallmark features of the diseases.
Holden Thorp is to be the new editor-in-chief of Science and its related journals.
A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.
Adelaide University has suspended the head of an ancient DNA lab as its investigation of workplace bullying continues, Australia's ABC News reports.
In PNAS this week: gene expression profiles of adipocyte subtypes, computational approach for improving plant expressome analysis, and more.